Major progress in the licensing business and several new partnerships for wound care Second quarter (April-June 2021) Revenues amounted to SEK 46.0 (48.2) million, a decrease of 5%. Adjusted for currencies revenues increased 5%. EBITDA amounted to SEK 1.8 (10.5) million with an EBITDA margin of 4% (22%). Operating profit amounted to SEK -10.0...
Following successful European regulatory clearance and market launch of Bactiguard-coated Zimmer Biomet trauma implants (ZNN Bactiguard), the initial USD 1 million milestone payment has been released. “I am excited about our partnership with Zimmer Biomet and proud of the progress we have made thus far”, says Cecilia Edström,...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 28 April 2021, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2020 and decided that no dividend for the financial year 2020 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board...
Continued high activity in the first quarter – infection prevention a global sustainability issue First quarter (January-March 2021) Revenues amounted to SEK 41.8 (48.1) million, a decrease by 13%. Adjusted for currencies the decrease was 3%. EBITDA amounted to SEK 1.9 (14.4) million with an EBITDA-margin of 5% (30%). Operating profit amounted...
The annual report for Bactiguard Holding AB (publ) 2020 is now available at www.bactiguard.com. The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 28 and can be ordered by sending an email to: info@bactiguard.com. This information is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Wednesday, 28 April 2021. Due to the ongoing pandemic, the Company’s board of directors has decided that the AGM will be conducted without the physical presence of...
Recovery in the fourth quarter – Infection prevention key in future healthcare Fourth quarter (October-December 2020) Revenues amounted to SEK 55.6 (59.8) million, a decrease by 7% (adjusted for currency -2%). EBITDA amounted to SEK 4.9 (12.2) million with an EBITDA-margin of 9% (20%). Operating profit amounted to SEK -6.4 (1.7) million. Net...
The Nomination Committee of Bactiguard Holding AB (publ) has today held a meeting and decided to propose Thomas von Koch as new Chairman of the Board at the Annual General Meeting on April 28, 2021. The current Chairman of the Board, Christian Kinch, is proposed by the Nomination Committee as new Deputy Chairman of the Board. Cecilia Edström has...
Cecilia Edström has today informed the Board that she wishes to resign as CEO of Bactiguard Holding AB (publ) after seven years in the Executive Management team. The Board will therefore initiate the recruitment of a new CEO. Cecilia Edström will continue in her role as CEO until her successor has been appointed and is available for re-election...
Today, Bactiguard-coated Zimmer Biomet orthopaedic trauma implants received European regulatory clearance and CE mark. Preparations for registering the implants in the U.S. market are also ongoing.“I am very pleased that the CE mark has been secured for Bactiguard-coated Zimmer Biomet trauma implants. This clearance will pave the way for...
